Cerus Corporation  

(Public, NASDAQ:CERS)   Watch this stock  
Find more results for Chrystal Green�
4.38
-0.06 (-1.35%)
Real-time:   10:13AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.32 - 4.43
52 week 3.48 - 7.03
Open 4.41
Vol / Avg. 71,690.00/1.41M
Mkt cap 393.91M
P/E     -
Div/yield     -
EPS -0.50
Shares 89.93M
Beta 1.76
Inst. own 57%
Apr 29, 2015
Q1 2015 Cerus Corp Earnings Release (Estimated) Add to calendar
Mar 3, 2015
Cerus Corp at Cowen Health Care Conference
Feb 26, 2015
Q4 2014 Cerus Corp Earnings Call
Feb 26, 2015
Q4 2014 Cerus Corp Earnings Release
Dec 17, 2014
Cerus Corp to Discuss US FDA Approval of INTERCEPT Plasma
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -206.67% -105.65%
Operating margin -132.06% -121.49%
EBITD margin - -120.94%
Return on average assets -99.51% -46.70%
Return on average equity -180.23% -91.28%
Employees 115 -
CDP Score - -

Address

2550 Stanwell Drive
CONCORD, CA 94520
United States - Map
+1-925-2886000 (Phone)
+1-925-2886001 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the Company's technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses (for example, HIV, West Nile, SARS, hepatitis B and C), bacteria and parasites, as well as potentially harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company has commercial rights for its intercepts Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, has received Conformite Europeene (CE) marks.

Officers and directors

Daniel N. Swisher Jr. Independent Chairman of the Board
Age: 51
Bio & Compensation  - Reuters
William M. Greenman President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Kevin D. Green Chief Financial Officer, Vice President - Finance
Age: 42
Bio & Compensation  - Reuters
Caspar Hogeboom President, Cerus Europe
Age: 55
Bio & Compensation  - Reuters
Laurence M. Corash M.D. Senior Vice President, Chief Medical and Chief Scientific Officer, Director
Age: 70
Bio & Compensation  - Reuters
Carol M. Moore Senior Vice President - Regulatory Affairs, Quality and Clinical
Age: 64
Bio & Compensation  - Reuters
Chrystal N. Menard Chief Legal Officer
Age: 43
Bio & Compensation  - Reuters
Timothy Bruce Anderson Independent Director
Age: 67
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 50
Bio & Compensation  - Reuters
Gail Gaumer Schulze Independent Director
Age: 62
Bio & Compensation  - Reuters